[go: up one dir, main page]

WO1996034010A3 - Inhibiteurs de la farnesyle transferase - Google Patents

Inhibiteurs de la farnesyle transferase Download PDF

Info

Publication number
WO1996034010A3
WO1996034010A3 PCT/US1996/003975 US9603975W WO9634010A3 WO 1996034010 A3 WO1996034010 A3 WO 1996034010A3 US 9603975 W US9603975 W US 9603975W WO 9634010 A3 WO9634010 A3 WO 9634010A3
Authority
WO
WIPO (PCT)
Prior art keywords
farnesyl
ca1a2x
inhibitors
thiol
analogs
Prior art date
Application number
PCT/US1996/003975
Other languages
English (en)
Other versions
WO1996034010A2 (fr
Inventor
S Jane Desolms
Original Assignee
Merck & Co Inc
S Jane Desolms
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, S Jane Desolms filed Critical Merck & Co Inc
Priority to JP8528692A priority Critical patent/JPH11502822A/ja
Priority to EP96929648A priority patent/EP0837875A4/fr
Priority to AU68950/96A priority patent/AU708620B2/en
Publication of WO1996034010A2 publication Critical patent/WO1996034010A2/fr
Publication of WO1996034010A3 publication Critical patent/WO1996034010A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention comporte des analogues du motif structural CA1A2X de la protéine Ras, laquelle est modifiée par farnésylation in vivo. Ces analogues de CA1A2X inhibent la farnésyle transférase ainsi que la farnésylation de certaines protéines. En outre, ces analogues de CA1A2X diffèrent de ceux précédemment décrits en tant qu'inhibiteurs de la farnésyle transférase, en ce qu'ils sont dépourvus d'une fraction thiol. Cette absence de fraction thiol offre des avantages uniques, en termes d'un meilleur comportement pharmacocinétique de ces analogues chez les animaux, d'une prévention de réactions chimiques dépendant des thiols, telles qu'une autoxydation rapide et une formation de disulfure avec les thiols endogènes, et d'une toxicité systématique réduite. Les composés selon l'invention comprennent également une fraction amine cyclique en position A2 du motif structural. On décrit encore dans cette invention des compositions chimiothérapeutiques contenant ces inhibiteurs de farnésyle transférase, ainsi que des procédés de production de ceux-ci.
PCT/US1996/003975 1995-03-29 1996-03-25 Inhibiteurs de la farnesyle transferase WO1996034010A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8528692A JPH11502822A (ja) 1995-03-29 1996-03-25 ファルネシル−タンパク質トランスフェラーゼ阻害剤
EP96929648A EP0837875A4 (fr) 1995-03-29 1996-03-25 Inhibiteurs de la farnesyle transferase
AU68950/96A AU708620B2 (en) 1995-03-29 1996-03-25 Inhibitors of farnesyl-protein transferase

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41282895A 1995-03-29 1995-03-29
US41262695A 1995-03-29 1995-03-29
US441995P 1995-09-27 1995-09-27
US60/004,419 1995-09-27
US08/412,828 1995-09-27
US08/412,626 1995-09-27

Publications (2)

Publication Number Publication Date
WO1996034010A2 WO1996034010A2 (fr) 1996-10-31
WO1996034010A3 true WO1996034010A3 (fr) 1996-12-12

Family

ID=56289685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/003975 WO1996034010A2 (fr) 1995-03-29 1996-03-25 Inhibiteurs de la farnesyle transferase

Country Status (1)

Country Link
WO (1) WO1996034010A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703241A (en) * 1995-10-16 1997-12-30 Merck & Co., Inc. Inhibitor of farnesyl-protein transferase
EP0891352A4 (fr) * 1996-04-03 2001-08-16 Merck & Co Inc Inhibiteurs de la farnesyl-proteine transferase
US9079929B2 (en) 2011-10-14 2015-07-14 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
IN2014CN02806A (fr) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
EP2766346B1 (fr) 2011-10-14 2017-03-29 Bristol-Myers Squibb Company Composés de tétrahydroisoquinoléine substitués comme inhibiteurs du facteur xia
EP2906552B1 (fr) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Composés de tetrahydroisoquinoline substitués par guanidine en tant qu'inhibiteurs de factor xia
US9920034B2 (en) 2012-10-12 2018-03-20 Bristol-Myers Squibb Company Crystalline forms of a factor XIa inhibitor
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
NO2760821T3 (fr) 2014-01-31 2018-03-10
WO2015116885A1 (fr) 2014-01-31 2015-08-06 Bristol-Myers Squibb Company Macrocycles à groupes hétérocycliques p2' servant d'inhibiteurs du facteur xia
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238922A (en) * 1991-09-30 1993-08-24 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5326773A (en) * 1992-10-29 1994-07-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5340828A (en) * 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5504212A (en) * 1992-10-29 1996-04-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238922A (en) * 1991-09-30 1993-08-24 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5340828A (en) * 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5326773A (en) * 1992-10-29 1994-07-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5504212A (en) * 1992-10-29 1996-04-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, September 1989, Volume 49, BOS, "Ras Oncogenes in Human Cancer: A Review", pages 4682-4689. *
NATURAL MEDICINE, August 1995, Vol. 1, No. 8, KOHL et al., "Inhibition of Farnesyltransferase Induces Regression of Mammary and Salivary Carcinomas in Ras Transgenic Mice", pages 792-797. *
See also references of EP0837875A4 *

Also Published As

Publication number Publication date
WO1996034010A2 (fr) 1996-10-31

Similar Documents

Publication Publication Date Title
WO1996034010A3 (fr) Inhibiteurs de la farnesyle transferase
WO1996010034A3 (fr) Inhibiteurs de la transferase de proteines farnesylees exempts de thiol
WO1997038665A3 (fr) Inhibiteurs de la farnesyl-proteine transferase
RU95109935A (ru) Ингибиторы фарнезил-белковой трансферазы, фармацевтическая композиция, способы лечения
MX9707459A (es) Inhibidores de farnesil-proteina transferasa, composiciones que los contienen y uso de las composiciones.
AU5455394A (en) Inhibitors of farnesyl-protein transferase
IL120266A (en) Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP1123120A4 (fr) Formulation d'aerosol medicinal
WO2002057259A3 (fr) Composes de pyrazole utiles en tant qu'inhibiteurs de proteine kinase
WO2000034437A3 (fr) Inhibiteurs de prenyl-proteine transferase
WO1996031525A3 (fr) Inhibiteurs de la farnesyl-proteine transferase
AU589431B2 (en) Nitrogen containing heterocyclic oxo and thio compounds useful as pesticides
AU1634288A (en) Cyclic anticoagulant peptides
IL86439A0 (en) Cyclic anticoagulant peptides
FR2572399B1 (fr) Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
WO1996023771A3 (fr) Inhibiteurs de l'agregation plaquettaire
GR3034615T3 (en) Aminophenylalanine derivatives, process for their production, their use and agents containing them as anti-coagulants.
GR3033239T3 (en) Stable pharmaceutical compositions containing hybrid alpha-interferon.
WO2001076390A3 (fr) Aromatisation d'un aliment par incorporation d'une quantite effective d'au moins un compose de formule r1-s-r2 dans laquelle r1 et r2 representent un atome ou un groupe specifique
WO2000039130A3 (fr) Inhibiteurs de la prenyl-transferase
WO2000034239A3 (fr) Inhibiteurs de prenyl-proteine transferase
DK0530407T3 (da) Substituerede nukleosidderivater, fremgangsmåder til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
Breslin et al. Inhibitors of farnesyl-protein transferase
KR900006282A (ko) 피롤리딘 유도체
TW375525B (en) Inhibitors for morphine-like drug induced emesis containing active components (R)-1-ethyl-4-methyl hexahydro-1H-1,4-diazepine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US US US US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1996929648

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2216532

Country of ref document: CA

Ref country code: CA

Ref document number: 2216532

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 528692

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996929648

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996929648

Country of ref document: EP